PharmAust: Successfully progresses canine trials and other operations
- PharmAust (PAA) claims its business progressed “very successfully” in the 2019 December quarter
- Its phase 2 trials also using monepantel to treat dogs with cancer saw positive progress
- Then the company is extending the study with a new dosage and hopes to uncover a successful drug for canine treatment
- The company has submitted and MPL human trial paper for publication in a peer review journal
- In addition, its wholly-owned subsidiary, Epichem, had a positive quarter and achieved revenue of almost $970,000
- Shares in PharmAust remain flat and are trading for 9.6 cents each